Psoriasis is an autoinflammatory disease of skin, affecting 150 Mio. people worldwide. While standard therapies show high response rates, they are also expensive and frequently lead to the development of side effects or therapy resistance. Therefore, new therapy approaches are needed. Previously, we identified a signaling pathway that is upregulated in psoriasis, while its inhibition blocks the development of psoriasis. Thus, we will now screen for novel small molecule inhibitors that are able to specifically inhibit this pathway, thereby identifying a novel therapy approach for the treatment of psoriasis. We will intensively characterize these inhibitors by applying various in vitro and in vivo models of psoriasis. Thus, with this project approach, we are confident to identify new inhibitors for the treatment of psoriasis, which act specifically and locally, therefore reducing unwanted side-effects or the development of therapy resistance.